WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

Insights from 2024 WCLC

P. Lee

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

GI Cancers: Hot Topics in 2024

Yale Cancer Center

J. Lacy

ESMO 2024 Summary: Late-Line Therapy in mCRC - How to Choose

2024 ESMO Annual Meeting Insights Hub

H. Hochster

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ESMO 2024 Summary: Neoadjuvant Colon Cancer Treatment - Recent Clini…

2024 ESMO Annual Meeting Insights Hub

J. Taieb

The NADINA Trial - A Paradigm Shift in Melanoma Treatment

Oncology Data Advisor

M. Hadfield

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

2024 ASCO® Annual Meeting Insights Hub

S. Patel

Clinical Applications of ctDNA in Breast Cancer Diagnosis and Manage…

University of Miami Sylvester Comprehensive Cancer Center

D. Tripathy

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

The Importance of 1L Biomarkers in CRC

Nicholas DeVito

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ecancer

C. Booth

Early-Onset CRC: A New Epidemic With Knowns and Unknowns

Ibrahim Sahin

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

ESMO 2024 Summary: The Emerging Global Epidemic of Early-Onset Cance…

2024 ESMO Annual Meeting Insights Hub

S. Ogino

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel